Clear Search

Showing 1 result for “Zhu D” published 2022.

November 2022

Empagliflozin in Patients with Chronic Kidney Disease

N Engl J Med. 2022; online ahead of print

Among a wide range of at-risk patients with CKD, empagliflozin reduced progression of kidney disease or death from CV causes compared with placebo in the EMPA-KIDNEY trial.

Previous large trials involving patients with diabetic kidney disease and albuminuria have shown that SGLT2i reduce the risk of progression to kidney failure; however, most patients with CKD have low levels of albuminuria (UACR <300 mg/g) and do not have diabetes.

more…